References
- Yoon PW, Bastian B, Anderson RN, Collins JL, Jaffe HW. Centers for Disease Control and Prevention. Potentially preventable deaths from the five leading causes of death – United States, 2008–2010. Published 2 May 2014. Available from: http://www.cdc.gov/mmwr/pdf/wk/mm6317.pdf. [last accessed 19 Nov 2014].
- National Cancer Institute. Harms of smoking and health benefits of quitting. Available from: http://www.cancer.gov/cancertopics/factsheet/Tobacco/cessation. [last accessed 19 Nov 2014].
- Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, et al. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guidelines. U.S. Department of Health and Human Services. Available from: http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/update/treating_tobacco_use08.pdf. [last accessed 12 Nov 2014].
- Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry 2014;171:1199–1205.
- Chantix® [package insert]. New York City, NY: Pfizer, Inc; 2014.
- Zyban® [package insert]. Research Triangle Park, NC: GlaxoSmithKline LLC; 2014.
- Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotine antagonist. J Pharmacol Exp Ther 2000;295:321–327.
- Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained release combination therapy for smoking cessation. Nicotine Tob Res 2009;11:234–239.
- Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, Hurt RD. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers. JAMA 2014;311:155–163.
- Issa JS, Abe TO, Moura S, Santos PC, Pereira AC. Effectiveness of coadministration of varenicline, bupropion and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. Nicotine Tob Res 2013;15:1146–1150.
- Mochizuki T, Villemagne VL, Scheffel U, Dannals RF, Finley P, Zhan Y, Wagner HN Jr, Musachio JL. Nicotine induced up-regulation of nicotinic receptors in CD-1 mice demonstrated with an in vivo radiotracer: gender differences. Synapse 1998;30:116–118.
- Cosgrove KP, Esterlis I, McKee SA, Bois F, Seibyl JP, Mazure CR, Krishnan-Sarin S, et al. Sex differences in availability of b2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers. Arch Gen Psychiatry 2012;69:418–427.
- Brody AL, Mukhin AG, Mamoun MS, Luu T, Neary M, Liang L, Shieh J, et al. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment. JAMA Psychiatry 2014;71:797–805.
- Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR. Enantioselective effects of hydroxyl metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004;66:675–682.
- Brown AK, Mandelkern MA, Farahi J, Robertson C, Ghahremani DG, Sumerel B, Moallem N, London ED. Sex differences in striatal dopamine D2/D3 receptor availability in smokers and non-smokers. Int J Neuropsychopharmacol 2012;15:989–994.
- Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, Kuwabara H, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry 2006;59:966–974,
- Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Ramakers RM, van der Have F, Beekman FJ, van den Brink W, Booij J. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474–3477.
- Crunelle CL, de Wit TC, de Brain K, et al. Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high resolution pinhole [123I)IBZM SPECT study in rats. Nucl Med Biol 2012;39:640–644.
- Hong AS, Elrashidi MY, Schroeder DR, Ebbert JO. Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. J Subst Abuse Treat 2015;52:78–81.
- Paterson NE, Balfour DJ, Markou A. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 2007;25:3099–3108.
- ClinicalTrials.gov. Combination bupropion/varenicline for smoking cessation in male smokers (ConNic5). ClinicalTrials.gov identifier: NCT01806779. Available from: https://clinicaltrials.gov/ct2/show/NCT01806779?term=bupropion+and+varenicline+combination&rank=1. [last accessed 1 Jan 2015].
- ClinicalTrials.gov. Combining varenicline and bupropion for smoking cessation. ClinicalTrials.gov identifier: NCT00943618. Available from: https://clinicaltrials.gov/ct2/show/NCT00943618?term=bupropion+and+varenicline+combination&rank=8. [last accessed 1 Jan 2015].
- ClinicalTrials.gov. Mechanistic evaluation of pre-cessation therapies for smoking cessation. ClinicalTrials.gov identifier: NCT01406223. Available from: https://clinicaltrials.gov/ct2/show/NCT01406223?term=bupropion+and+varenicline+combination&rank=9. [last accessed 1 Jan 2015].